Negativity often gets a bad rap, but not when it comes to scientific research. Jamie Chang discusses how focusing on the negative can bring about positive advances in clinical research.
The open office concept has gained popularity in recent years, even becoming a sort of corporate status symbol suggesting that a company values openness, collaboration, and innovation. But what does the research show?
At Rho, we are proud of our commitment to supporting education and fostering innovative problem-solving for the next generation of scientists, researchers, and statisticians. One way we enjoy promoting innovation is by participating in the annual Industrial Math/Stat Modeling Workshop for Graduate Students (IMSM) hosted by the National Science Foundation-supported Statistical and Applied Mathematical Sciences Institute (SAMSI).
We believe our employees are our greatest asset. Attracting and retaining the most talented employees is critical to our success, so we put a huge emphasis on selecting the right people to join us and maintaining a culture where talented people want to stay long-term.
The fundamental assumption of clinical trials research is that we can take data from a relatively small, representative selection of subjects and generalize the results to the larger patient population. Unfortunately, our industry has long struggled with underrepresentation of important demographic groups, especially women, racial and ethnic minorities, and the elderly.
Causality assessments may differ between the site investigator and sponsor. It is important to understand the difference in assessments to ensure proper reporting and conduct through a trial. To better understand how to handle these situations it’s important to understand the differences.
The three-day event attracted over 580 data scientists, biostatisticians, statistical programmers, and IT professionals from across the US and around the world to focus on the theme of “Transformative Current and Emerging Best Practices.” Here is a round-up of some of the main themes of the conference and trends for our industry.
Cellular therapy has become increasingly-popular largely due to the fact that cells have the ability to carry out many complex functions that drugs cannot. When successful, cellular therapy can result in a more targeted and thus more effective treatment.
Artificial Intelligence apps use machine learning algorithms to improve the user experience. Machine learning (ML) algorithms make predictions and, in turn, learn from their own predictions resulting in improved performance over time. What does all this mean for clinical research?
The most recent Impact Report from the Tufts Center for the Study of Drug Development presented the results of a study including nearly 260 sponsor and CRO companies into clinical data management practices and experience. These findings represent the challenges those of us in clinical data management are struggling with given the current state of the clinical research industry and technological changes.
Attending PAINWeek this year was especially meaningful because pain research has been a major part of my career. Over the past 12 years, I have worked on more than 50
Staying cohesive through long and complex Parkinson’s disease trials Parkinson’s disease trials, like most clinical trials, are rarely a straight path from start to finish. Protocols evolve, real-world conditions change,
Six challenges in acute pain trials and one differentiator—coordinated execution We’ve all been there before. Your acute pain trial strategy is sound, the protocol looks solid, and everything progresses as
Acute pain trials start with assumptions. How you execute—when reality sets in—determines the outcome. When you’re designing an acute pain clinical trial, it’s perfectly normal to have some early assumptions
Early in clinical development, it’s easy to focus on what’s directly in front of you. After all, your goal is to hit milestones, generate strong data, and keep the program
Early clinical decisions shape regulatory risk and the path to approval Assumptions about study design and real-world execution don’t stay contained to a single milestone. Over time, they influence
Four scientific principles. One unifying concept. The Cohesion Effect experience. SCOPE Summit is a place where innovation thrives. Thousands of attendees and hundreds of exhibitors from around the world, all
When Tonix came to us, the stakes were high, and the timelines were tight. Their goal? To submit a New Drug Application (NDA) for TONMYA™ and, for the first time
Every CRO out there will tell you they’re site-centric, and on pitch decks, they use the right buzzwords to prove it. Curious. Collaborative. Dependable. Problem-solvers. Sound familiar? That’s great in
You’re responsible for showing risk oversight, protocol clarity, and a site-friendly design—but you’ve got a lean team, a looming trial, and no time to decode the 110-page ICH E6(R3) guidance.
